Mounjaro Injection Pen – 15 mg (Tirzepatide)

Injection Pen – 15 mg Mounjaro (Tirzepatide) contains tirzepatide, a next-generation therapy designed to improve glucose regulation and support weight management through a dual-hormone mechanism. The medication activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors, which play key roles in controlling blood sugar levels and appetite.

By stimulating insulin release when blood sugar levels are elevated and slowing the rate at which food leaves the stomach, tirzepatide helps stabilize glucose levels while reducing hunger signals. This combination can help individuals maintain better metabolic balance and reduce excessive calorie intake.

Each injection pen is pre-filled and designed for subcutaneous injection once per week, typically administered into the abdomen, thigh, or upper arm. The 15 mg dose is generally prescribed after lower doses have been tolerated and when stronger therapeutic support is required.

Maximum therapeutic strength
The 15 mg dose represents the highest recommended weekly dose for adults and may provide stronger metabolic and appetite-regulating effects.

Improved blood sugar regulation
Tirzepatide enhances insulin secretion and reduces glucose production in the liver, helping maintain more stable blood sugar levels.

Supports weight reduction
By slowing gastric emptying and reducing appetite signals, the medication can help users feel full longer and manage calorie intake more effectively.

Dual-hormone action
Unlike many single-pathway treatments, tirzepatide activates both GIP and GLP-1 receptors, which can enhance metabolic outcomes.

Convenient once-weekly dosing
The pre-filled injection pen simplifies administration and supports consistent treatment routines.

Injection Pen – 15 mg Mounjaro (Tirzepatide) is administered as a subcutaneous injection once per week.

Administration guidelines:

• Inject once weekly on the same day each week.

• The injection can be given with or without meals.

• Common injection sites include the abdomen, thigh, or upper arm.

• Rotate injection sites between doses to reduce irritation.

• Follow the dosing plan recommended by a healthcare professional.

• Combine treatment with a balanced diet and regular physical activity for optimal results.

The 15 mg dose is generally reached after gradual dose escalation (2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg) to minimize gastrointestinal side effects and allow the body to adapt to treatment.

Injection Pen – 15 mg Mounjaro (Tirzepatide) should be used only under medical supervision.

Important precautions include:

• Common side effects may include nausea, vomiting, diarrhea, constipation, and decreased appetite.

• The medication should not be used in individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

• Inform your healthcare provider about any other medications or medical conditions before starting treatment.

• Do not use if you are allergic to tirzepatide or any of the ingredients in the formulation.

• Store the injection pen according to manufacturer guidelines and keep it refrigerated until use.

If severe symptoms or allergic reactions occur, discontinue use and seek medical attention immediately.